Close
Almac
Achema middle east

FedEx to Exhibit Industry Leading Healthcare Solutions at BioLogistics World Asia 2024

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

FedEx Express, a subsidiary of FedEx Corp. and one of the world’s largest express transportation companies, will showcase its tailored transportation solutions for the healthcare sector at the BioLogistics World Asia 2024 in Singapore from 19th -21st March.

The healthcare industry, including clinical research, pharmaceuticals and biotech, diagnostics and medical equipment and supplies, has many unique and highly regulated logistics needs tied to the sensitivity of shipments. Requirements range from ensuring temperature integrity, speed of delivery, white glove support and contingency planning.

For decades, FedEx has been using its cold chain network and dedicated healthcare team to ship vaccines, biologics, and medical aid all around the world. FedEx uses its four Life Science Centers in the region including South Korea, Japan, Singapore and Mumbai and its fleet of more than 680 aircraft and 200,000 vehicles to move healthcare shipments using temperature-controlled solutions from -150oC to +25oC and real-time monitoring capabilities.

FedEx customized solutions for the industry comply with trade and regulatory requirements including FedEx® Clinical Care, an end-to-end solution for time and temperature sensitive bio-samples, kits, and investigation medicinal products. FedEx package tracking technology includes FedEx SenseAware which monitors multiple parameters in real time to ensure shipment integrity.

BioLogistics World Asia organized by IMAPAC, is a premier conference for biologics and logistics in the Asia Pacific region to demonstrate best practices in cold chain management. FedEx Healthcare team members will also be participating in the plenary sessions and will deliver a keynote speech on the region’s rapidly evolving healthcare needs.

FedEx is committed to making healthcare shipments easier, faster, and more secure. Find more insights on healthcare logistics at FedEx Business Insights.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »